VBL Therapeutics (VBLT) halted, news pending
Pre-Open Stock Movers: VBL Therapeutics (NASDAQ:VBLT) 79% LOWER; announced top-line data from the Phase 3 OVAL clinical trial of ofra-vec (ofranergene obadenovec; VB-111) in...
As of late, it has definitely been a great time to be an investor in VBL Therapeutics (NASDAQ:VBLT) . The stock has moved higher by 5.5% in the past month, while it is also above...
Investors in Vascular Biogenics Ltd. (NASDAQ:VBLT) need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 15, 2018 $10.00...
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share...
Vascular Biogenics Ltd, former Medicard Ltd, is Israel- based clinical stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The Company has created a pipeline of therapeutics address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. It's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
|Moving Averages||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Sell|
|Technical Indicators||Buy||Neutral||Strong Buy||Strong Buy||Strong Sell|
|Summary||Strong Buy||Buy||Strong Buy||Strong Buy||Strong Sell|